Mitochondrial ATAD3A combines with GRP78 to regulate the WASF3 metastasis-promoting protein

Area of Science:

• Cell Biology
• Molecular Oncology
• Cancer Therapeutics

Background:

• AAA domain containing 3A (ATAD3A) is a mitochondrial protein linked to poor breast cancer survival.
• Its precise function and interactions in cancer remain largely unknown.

Purpose of the Study:

• To elucidate the function of ATAD3A in cancer.
• To investigate the interaction between ATAD3A and the metastasis-promoting protein WASF3.
• To explore the therapeutic potential of targeting ATAD3A.

Main Methods:

• Mass spectrometry to identify ATAD3A interacting proteins.
• Gene knockdown and silencing in cancer cell lines (breast and colon).
• In vivo tumor growth and metastasis studies in immunocompromised mice.
• Analysis of protein stabilization mechanisms involving HSP70, GRP78, and ATAD3A.
• Mitochondrial proteolysis experiments.

Main Results:

• ATAD3A interacts with WASF3, and ATAD3A knockdown decreases WASF3 levels and suppresses cancer cell invasion, anchorage-independent growth, and metastasis.
• ATAD3A stabilizes WASF3 at the mitochondrial membrane, potentially bridging endoplasmic reticulum (ER) and mitochondria.
• ATAD3A regulates GRP78-mediated WASF3 stability, impacting CDH1/E-cadherin expression.
• Pharmacologic inhibition of ATAD3A shows potential as a cancer therapy.

Conclusions:

• ATAD3A plays a critical role in stabilizing WASF3, promoting cancer cell invasion, growth, and metastasis.
• The ATAD3A-WASF3-GRP78 axis represents a novel pathway linking ER and mitochondria in cancer.
• Targeting ATAD3A offers a promising therapeutic strategy for various human cancers.